MedTrace Logo

Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

NCT00651703 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2010-11-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine alone or in combination with different adjuvants.

Conditions

  • Malignant Melanoma

Interventions

BIOLOGICAL

CYT004-MelQbG10 + Montanide

BIOLOGICAL

CYT004-MelQbG10 + Montanide + Imiquimod

BIOLOGICAL

CYT004-MelQbG10 + Imiquimod

BIOLOGICAL

CYT004-MelQbG10 intra nodal injection

Sponsors & Collaborators

  • Cytos Biotechnology AG

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-12-31
Completion
2010-07-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00651703 on ClinicalTrials.gov